Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal

share with twitter share with LinkedIn share with facebook
07/31/2020 | 05:56pm EDT
FILE PHOTO: A GSK logo is seen at the GSK research centre in Stevenage

The U.S. government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for COVID-19 vaccines to cover 50 million people and to underwrite the drugmakers' testing and manufacturing, the companies said on Friday.

The drugmakers also said they are in advanced discussions to supply up to 300 million doses of the experimental vaccine for the 27-country European Union.

The U.S. award is the biggest yet from 'Operation Warp Speed', the White House initiative aimed at accelerating access to vaccines and treatments to fight COVID-19, the respiratory disease caused by the novel coronavirus.

The deal, announced by the U.S. Department of Health and Human Services and Department of Defense, works out at a cost of around $42 per person inoculated.

That is almost identical to the $40 per patient the U.S. agreed to pay Pfizer Inc and BioNTech SE when it inked a nearly $2 billion deal for 50 million courses of that potential vaccine last week.

The Sanofi-GSK deal is for 100 million doses, at two per person, and gives the U.S. government an option to purchase an additional 500 million doses at an unspecified price. Sanofi and GSK plan to start clinical trials for the vaccine in September.

Sanofi executive Clement Lewin said the companies had not yet agreed with the U.S. on a specific price for the additional doses.

GSK said in a statement that more than half of the total funding will go into further development of the vaccine, including clinical trials, with the remainder used for a manufacturing ramp-up and delivery of doses.

The two companies' inoculation is combination of a vaccine based on Sanofi's flu shots and a complementary technology from GSK called an adjuvant, designed to improve the vaccine's potency.

Sanofi will receive the bulk of the proceeds from the deal.

It marks the second contract for the Franco-British pair's vaccine candidate after they agreed earlier this week to supply 60 million doses to the British government.

Reuters reported last week that Pfizer's deal was expected to set a pricing benchmark for future deals between drugmakers and governments.

Moderna Inc and Pfizer began two 30,000-subject trials of COVID-19 vaccines on Monday that could clear the way for regulatory approval and use by the end of 2020.

(Reporting by Michael Erman and Carl O'Donnell in New York; Additional reporting by Ludwig Burger in Frankfurt and Deena Beasley in Los Angeles; editing by Jan Harvey and Grant McCool)

By Michael Erman and Carl O'Donnell

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -2.44% 82.11 Delayed Quote.142.36%
GLAXOSMITHKLINE PLC 2.51% 1569.4 Delayed Quote.-14.01%
MODERNA, INC. -4.55% 74.1 Delayed Quote.278.83%
PFIZER LIMITED 0.95% 4271.65 End-of-day quote.1.12%
PFIZER, INC. -0.67% 38.48 Delayed Quote.-1.79%
SANOFI 1.75% 90.18 Real-time Quote.-1.19%
share with twitter share with LinkedIn share with facebook
07:15aGilead Shows the Dangers of Covid-19 Drug Mania -- Heard on the Street
07:03aNext big COVID-19 treatment may be manufactured antibodies
02:35aGlaxoSmithKline and Sanofi to Supply EU With 300 Million Covid-19 Doses
08/01WHAT'S NEWS : World-Wide -- WSJ
07/31EU in talks to secure Sanofi deal for coronavirus vaccine
07/31U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal
07/31Health Care Down On Tech Rotation -- Health Care Roundup
07/31GLAXOSMITHKLINE : REFILE-Sanofi, Glaxo advance talks to supply up to 300 mln COV..
07/31U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal
07/31Sanofi, GlaxoSmithKline Ink Coronavirus Vaccine Deal With U.S. -- Update
More news
Sales 2020 35 226 M 45 893 M 45 893 M
Net income 2020 4 365 M 5 687 M 5 687 M
Net Debt 2020 23 149 M 30 159 M 30 159 M
P/E ratio 2020 15,6x
Yield 2020 5,23%
Capitalization 76 135 M 100 B 99 191 M
EV / Sales 2020 2,82x
EV / Sales 2021 2,69x
Nbr of Employees 99 437
Free-Float 91,1%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 1 875,69 GBX
Last Close Price 1 529,80 GBX
Spread / Highest target 46,4%
Spread / Average Target 22,6%
Spread / Lowest Target 0,47%
EPS Revisions
Emma N. Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.08%383 760
ROCHE HOLDING AG0.67%296 096
PFIZER, INC.-1.79%213 750
MERCK & CO., INC.-11.78%202 534
NOVARTIS AG-17.88%182 470